ABBOTT LABORATORIES

ABT NYSE CIK: 0000001800

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation IL
Business Address 100 ABBOTT PARK ROAD, ABBOTT PARK, IL, 60064-3500
Mailing Address 100 ABBOTT PARK ROAD, ABBOTT PARK, IL, 60064-3500
Phone 2246676100
Fiscal Year End 1231
EIN 360698440

Financial Overview

FY2025

$52.13B
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
3 Initial insider ownership report March 25, 2026 View on SEC
4 Insider stock transaction report March 25, 2026 View on SEC
8-K Current report of material events March 23, 2026 View on SEC
DEF 14A Definitive proxy statement March 13, 2026 View on SEC

Annual Reports

10-K February 20, 2026
  • Achieved robust total sales of $39.7 billion in 2024, a 3.4% increase, demonstrating resilience despite declining COVID-19 testing revenue.
  • Delivered strong profitability with $7.5 billion net income and $4.30 diluted EPS in 2024, alongside $9.0 billion in operating cash flow.
View Analysis

Material Events

8-K Acquisition March 23, 2026
High Impact
  • Abbott acquired Exact Sciences, a leader in cancer screening and diagnostics, known for Cologuard.
  • Significantly expands Abbott's high-growth diagnostics business, especially in cancer detection and colorectal cancer screening.
View Analysis

Insider Trading

STRONG BUY 8 insiders 9 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.